Skip to main content

Value Stock - Dividend - Research Selection


Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022

Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022, after the U.S. financial market

ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J., BOCA RATON, Fla. and Myrtle Beach, SC. , Oct. 31, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has rec

ADMA Biologics receives FDA approval for seventh plasma collection center

ADMA Biologic announced t... ADMA

Adma Biologics: Understanding The Risks Of Blood Plasma Collection

Adma Biologics saw its share price reach an all-time low in October 2021. Is now the time to invest? Read more about Adma and its efforts to market and sell plasma-derived therapies.

ADMA Biologics, Inc. (NASDAQ:ADMA) is largely controlled by institutional shareholders who own 53% of the company

Every investor in ADMA Biologics, Inc. ( NASDAQ:ADMA ) should be aware of the most powerful shareholder groups. And the...

ADMA Biologics initiated with a Buy at Mizuho

Mizuho analyst Anthony Pe... ADMA

Top Penny Stocks for October 2022

Penny stocks are those which typically trade at $5 per share or less. Most penny stocks represent small companies that likely trade via over-the-counter (OTC) transactions, although some do trade on primary exchanges. Investing in penny stocks can thus be especially risky and may also entail higher trading costs.

7 A-Rated Stocks to Buy for Less Than $10

Some stocks under $10 are cheap for a reason, but there are other stocks under $10 that are solid long-term investments. There are all sorts of equities from which to choose when building your portfolio. While there are arguably great names at high prices, it’s important that investors don’t overlook quality stocks to buy for less than $10. Some of these names don’t carry the cache or prominence of a blue-chip stock, but the returns that they offer can be enticing.InvestorPlace - Stock Market Ne

7 A-Rated Stocks Under $10 to Buy

While stocks under $10 don't carry the cache of blue-chip stocks, the returns that they offer can be enticing.

7 Top-Rated Biotech Stocks to Buy for Q4

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter. The new National Biotechnology and Biomanufacturing Initiative is designed to encourage biotech production in the U.S. An executive order signed by President Joe Biden on Sept. 12, was followed by a White House summit featuring Cabinet-level initiatives that will increase the nation’s biotech and biomanufacturing capabilities. This